<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Proton pump inhibitors for chronic obstructive pulmonary disease - Kikuchi, S - 2020 | Cochrane Library</title> <meta content="Proton pump inhibitors for chronic obstructive pulmonary disease - Kikuchi, S - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013113.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Proton pump inhibitors for chronic obstructive pulmonary disease - Kikuchi, S - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013113.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013113.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Proton pump inhibitors for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Shino Kikuchi" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine" name="citation_author_institution"/> <meta content="shino_k@kuhp.kyoto-u.ac.jp" name="citation_author_email"/> <meta content="Hissei Imai" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Yoko Tani" name="citation_author"/> <meta content="Graduate School of Medicine,Osaka City University" name="citation_author_institution"/> <meta content="Tomoko Tajiri" name="citation_author"/> <meta content="Graduate School of Medical Sciences, Nagoya City University" name="citation_author_institution"/> <meta content="Norio Watanabe" name="citation_author"/> <meta content="Kyoto University School of Public Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD013113.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013113.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013113.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013113.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Disease Progression; Lansoprazole [*therapeutic use]; Proton Pump Inhibitors [*therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy, prevention &amp; control]; Randomized Controlled Trials as Topic; Respiratory Tract Infections [epidemiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013113.pub2&amp;doi=10.1002/14651858.CD013113.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013113\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013113\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013113.pub2",title:"Proton pump inhibitors for chronic obstructive pulmonary disease",firstPublishedDate:"Aug 25, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013113.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013113.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013113.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013113.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013113.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013113.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013113.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013113.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013113.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013113.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3024 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013113.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0063"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-sec-0057"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/appendices#CD013113-sec-0068"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/table_n/CD013113StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/table_n/CD013113StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Proton pump inhibitors for chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#CD013113-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Shino Kikuchi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#CD013113-cr-0005">Hissei Imai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#CD013113-cr-0006">Yoko Tani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#CD013113-cr-0007">Tomoko Tajiri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information#CD013113-cr-0008">Norio Watanabe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information/en#CD013113-sec-0079">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013113.pub2">https://doi.org/10.1002/14651858.CD013113.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013113-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013113-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013113-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013113-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013113-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013113-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013113-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013113-abs-0001" lang="en"> <section id="CD013113-sec-0001"> <h3 class="title" id="CD013113-sec-0001">Background</h3> <p>Chronic obstructive pulmonary disease (COPD) is a common and progressive disease characterised by chronic cough, airflow limitation and recurrent exacerbations. Since COPD exacerbations are linked to rising mortality and reduced quality of life, the condition poses a substantial burden on individuals, society and the healthcare system. Effective management of COPD exacerbations that includes treatment of related conditions in people with COPD is thus recognised as a relevant clinical question and an important research topic. Gastroesophageal reflux disease (GERD) is a known comorbidity of COPD, and pulmonary microaspiration of gastric acid is thought to be a possible cause of COPD exacerbations. Therefore, reducing gastric acid secretion may lead to a reduction in COPD exacerbations. Proton pump inhibitors (PPIs) are one of the most commonly prescribed medications and are recommended as first‐line therapy for people with GERD because of their inhibitory effects on gastric acid secretion. Treatment with PPIs may present a viable treatment option for people with COPD. </p> </section> <section id="CD013113-sec-0002"> <h3 class="title" id="CD013113-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of PPI administration for people with COPD, focusing on COPD‐specific outcomes. </p> </section> <section id="CD013113-sec-0003"> <h3 class="title" id="CD013113-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Register of Trials and conventional clinical trial registers from inception to 22 May 2020. We also screened bibliographies of relevant studies. </p> </section> <section id="CD013113-sec-0004"> <h3 class="title" id="CD013113-sec-0004">Selection criteria</h3> <p>Parallel‐group and cluster‐randomised controlled trials (RCTs) that compared oral PPIs versus placebo, usual care or low‐dose PPIs in adults with COPD were eligible for inclusion. We excluded cross‐over RCTs, as well as studies with a duration of less than two months. </p> </section> <section id="CD013113-sec-0005"> <h3 class="title" id="CD013113-sec-0005">Data collection and analysis</h3> <p>Two independent review authors screened search results, selected studies for inclusion, extracted study characteristics and outcome data, and assessed risk of bias according to standard Cochrane methodology. We resolved discrepancies by involving a third review author. Primary outcomes of interest were COPD exacerbations, pneumonia and other serious adverse events. Secondary outcomes were quality of life, lung function test indices, acute respiratory infections and disease‐specific adverse events. We extracted data on these outcome measures and entered into them into Review Manager software for analysis. </p> </section> <section id="CD013113-sec-0006"> <h3 class="title" id="CD013113-sec-0006">Main results</h3> <p>The search identified 99 records, and we included one multicentre RCT that randomised 103 adults with COPD. The 12‐month RCT compared an oral PPI (lansoprazole) and usual care versus usual care alone. It was conducted at one tertiary care hospital and three secondary care hospitals in Japan. This study recruited participants with a mean age of 75 years, and excluded people with symptoms or history of GERD. No placebo was used in the usual care arm. </p> <p>Among the primary and secondary outcomes of this review, the study only reported data on COPD exacerbations and acute respiratory infections (the common cold). As we only included one study, we could not conduct a meta‐analysis. </p> <p>The included study reported that 12 of the 50 people on lansoprazole had at least one exacerbation over a year, compared to 26 out of 50 on usual care (risk ratio 0.46, 95% CI 0.26 to 0.81). The frequency of COPD exacerbations per person in a year was also lower in the PPI plus usual care group than in the usual care alone group（0.34 ± 0.72 vs 1.18 ± 1.40; P &lt; 0.001). The number of people with at least one cold over the year was similar in both groups: 26 people on lansoprazole and 27 people in the usual care group. We judged the evidence to be of low to very low certainty, according to GRADE criteria. </p> <p>The study reported no data on pneumonia and other serious adverse events, quality of life, lung function test indices or disease‐specific adverse events. The risk of bias was largely low or unclear for the majority of domains, though the performance bias was a high risk, as the study was not blinded. </p> </section> <section id="CD013113-sec-0007"> <h3 class="title" id="CD013113-sec-0007">Authors' conclusions</h3> <p>Evidence identified by this review is insufficient to determine whether treatment with PPIs is a potential option for COPD. The sample size of the included trial is small, and the evidence is low to very low‐certainty. The efficacy and safety profile of PPIs for people with COPD remains uncertain. Future large‐scale, high‐quality studies are warranted, which investigate major clinical outcomes such as COPD exacerbation rate, serious adverse events and quality of life. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013113-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013113-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013113-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013113-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013113-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013113-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013113-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013113-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013113-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013113-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013113-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013113-abs-0002" lang="en"> <h3>Proton pump inhibitors for chronic obstructive pulmonary disease</h3> <p><b>What is the aim of this review?</b> </p> <p>The review authors want to know whether proton pump inhibitors (PPIs) are effective in (a) reducing chronic obstructive pulmonary disease (COPD) exacerbations, and (b) improving quality of life for people with COPD. We searched for randomised trials to answer this question and found only one study, with 103 participants. </p> <p><b>Key message</b> </p> <p>Giving PPIs to people with COPD may reduce the frequency of COPD exacerbations. However, further high‐quality studies are needed to be more certain. Future studies should include different types of PPIs. </p> <p><b>What was studied in the review?</b> </p> <p>This study specifically looked at COPD. COPD is a common respiratory disease, characterised by cough with mucus and breathlessness. COPD is one of the leading causes of death worldwide, and reduces quality of life. COPD exacerbation is associated with hospitalisation and death, placing a large burden on both society and the economy. COPD exacerbation is caused by different conditions that require different therapies. </p> <p>Gastroesophageal reflux disease (GERD) is one cause of COPD exacerbation. GERD is a common gastrointestinal disease caused by reflux of stomach acid into the oesophagus (food pipe) and lungs. This gives people the symptoms of heartburn and cough. When people have GERD, they are given PPIs to treat it. These work by reducing the amount of stomach acid. While PPIs are effective for treating symptoms of GERD, it is unclear whether adding PPIs to usual care reduces the frequency of COPD exacerbations or improves the quality of life for people with COPD. </p> <p><b>What are the main results of the review?</b> </p> <p>We found only one relevant study. It was from a university hospital and three city hospitals in Japan. This study compared the effects of a PPI plus usual care against usual care alone in people with COPD who had no history or symptoms of GERD. The researchers investigated changes in the frequency of COPD exacerbations and the common cold over a 12‐month period. This study used a 15 mg daily dose of a PPI called lansoprazole. There was low‐certainty evidence of a reduction in the number of people on lansoprazole who had COPD exacerbations compared with people who had usual care, and very low‐certainty evidence that similar numbers of people in each group had at least one common cold. </p> <p>The review authors did not find any studies that described the effects of PPIs on pneumonia and serious adverse events, quality of life, lung function, or disease‐specific adverse events. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We ran the latest search for studies on 22 May 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013113-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013113-sec-0063"></div> <h3 class="title" id="CD013113-sec-0064">Implications for practice</h3> <section id="CD013113-sec-0064"> <p>Findings of this review are based on only one low quality randomised controlled trial (RCT), for which reporting of clinically significant results was limited. The evidence was limited by various factors, including the study being potentially underpowered, and limited reporting of important outcomes of clinical benefit and harm. There is currently insufficient evidence to guide meaningful clinical practice decisions as to the potential benefits and risks of proton pump inhibitors (PPIs) for people with chronic obstructive pulmonary disease (COPD). </p> </section> <h3 class="title" id="CD013113-sec-0065">Implications for research</h3> <section id="CD013113-sec-0065"> <p>Key aims of the care pathway for people with COPD are to reduce the rate of COPD exacerbation and to improve overall quality of life. Existing research has suggested that gastroesophageal reflux disease (GERD) is a comorbidity of COPD. However, the precise effects of PPIs on COPD are yet to be comprehensively evaluated. This is an emerging and important research direction, given that PPIs are commonly prescribed and readily available. In order to fully understand whether PPIs are a viable treatment option for COPD, researchers in the field of respiratory and gastroenterology medicine should seek to define the study population carefully, assess and report important outcomes, such as COPD exacerbations (using clear diagnostic criteria), pneumonia and other serious adverse events, quality of life, and pulmonary function. </p> <p>We recommend that people with COPD who have a history or symptoms of GERD should be excluded from the study population of future RCTs. The biggest reason is ethical issues. GERD can affect quality of life, and sometimes causes bleeding. Since PPIs are well established as first‐line drugs in the management of GERD (<a href="./references#CD013113-bbs2-0095" title="vanPinxterenB , NumansME , LauJ , deWitNJ , HunginAP , BonisPA . Short-term treatment of gastroesophageal reflux disease. Journal of General Internal Medicine2003;18(9):755-63. [PMID: 12950485]">van Pinxteren 2003</a>), we think that if we include people with GERD in the RCTs, we should use PPIs for those in the control group as well. However, excluding people with GERD from studies might reduce adverse events such as community‐acquired pneumonia (CAP). Therefore, it might be better to consider conducting a systematic review that includes non‐randomised studies of PPIs for people with COPD who have a history or symptoms of GERD. </p> <p>The diagnosis of GERD is made by a combination of several diagnostic modalities, including symptom presentation, response to antacid therapy, upper gastrointestinal endoscopy, histological examination, and oesophageal pH monitoring (<a href="./references#CD013113-bbs2-0057" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology2013;108(3):308-28. [PMID: 23419381]">Katz 2013</a>; <a href="./references#CD013113-bbs2-0094" title="VakilN , vanZantenSV , KahrilasP , DentJ , JonesR . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. The American Journal of Gastroenterology2006;101(8):1900-20. [PMID: 16928254]">Vakil 2006</a>). However, in clinical practice, diagnosis of GERD is usually based on typical symptoms alone, and empirical PPI therapies are recommended as a reasonable approach to confirm GERD (<a href="./references#CD013113-bbs2-0057" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology2013;108(3):308-28. [PMID: 23419381]">Katz 2013</a>; <a href="./references#CD013113-bbs2-0094" title="VakilN , vanZantenSV , KahrilasP , DentJ , JonesR . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. The American Journal of Gastroenterology2006;101(8):1900-20. [PMID: 16928254]">Vakil 2006</a>). Oesophageal pH monitoring is a unique test used to check the frequency of reflux and the association of symptoms with reflux episodes. Although it has high sensitivity and specificity in the diagnosis of GERD, it is not a simple and quick test. A guideline recommends its use in certain situations, such as non‐erosive reflux disease, disease that is refractory to PPI therapy, and when the diagnosis of GERD is in question (<a href="./references#CD013113-bbs2-0057" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology2013;108(3):308-28. [PMID: 23419381]">Katz 2013</a>). Considering the implications for practice, we recommend using typical symptoms and empirical PPI therapy rather than oesophageal pH monitoring for the diagnosis of GERD in future studies. </p> <p>Moreover, future studies should employ a robust design of adequate power and methodological considerations (such as transparent reporting of randomisation methods, allocation concealment and blinding) to ensure that their are of high quality and relevance. Further evidence from robust, large‐scale trials investigating clinically relevant and patient‐centred outcomes such as COPD exacerbations and adverse events is warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013113-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013113-sec-0008"></div> <div class="table" id="CD013113-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PPI plus usual care versus usual care alone or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Usual care plus PPI compared to Usual care plus alone for chronic obstructive pulmonary disease</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic obstructive pulmonary disease<br/><b>Setting:</b> hospital outpatients in Japan (three secondary care hospitals and one tertiary care hospital)<br/><b>Intervention:</b> Usual care plus PPI<br/><b>Comparison:</b> Usual care plus alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Usual care plus alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Usual care plus PPI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Exacerbation rate (participants with one or more)</p> <p>study duration: 12 months</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.46<br/>(0.26 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The frequency of exacerbations improved with intervention.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>520 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1,000<br/>(135 to 421) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia and other serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function indices</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute respiratory infections</p> <p>study duration: 12 months</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.67 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear benefit or harm from PPI</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1,000<br/>(362 to 751) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>PPI</b> : proton pump inhibitor; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for imprecision: single small trial describes this result </p> <p><sup>b</sup>Downgraded by one level for study limitations: no blinding of participants and personnel </p> <p><sup>c</sup>Downgraded by one level for study limitations: the rate and number of common colds using outcomes that tend to be subjective </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013113-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013113-sec-0009"></div> <section id="CD013113-sec-0010"> <h3 class="title" id="CD013113-sec-0010">Description of the condition</h3> <p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline defines chronic obstructive pulmonary disease (COPD) as a common, preventable and treatable disease that has a significant detrimental impact on quality of life, and poses a substantial and growing economic and social burden (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). As a leading cause of global mortality, approximately three million deaths are attributed to COPD every year (<a href="./references#CD013113-bbs2-0099" title="World Health Organization. Chronic respiratory diseases. www.who.int/respiratory/en/ (accessed 22 January 2018).">WHO 2018</a>). People with COPD have a high frequency of respiratory complications and systemic comorbidities. These comorbidities, including cardiovascular diseases, osteoporosis, depression and gastroesophageal reflux disease (GERD), may potentiate the severity of COPD, leading to an increase in acute exacerbations (<a href="./references#CD013113-bbs2-0097" title="WedzichaJA , BrillSE , AllinsonJP , DonaldsonGC . Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine2013;11:181. [PMID: 23945277]">Wedzicha 2013</a>). </p> <p>The latest GOLD guidelines define COPD exacerbation as "an acute worsening of respiratory symptoms that results in additional therapy" (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). The economic impact of COPD exacerbations is substantial, since COPD exacerbations are linked to mortality, morbidity, and hospitalisations (<a href="./references#CD013113-bbs2-0074" title="PereraPN , ArmstrongEP , SherrillDL , SkrepnekGH . Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD2012;9(2):131-41. [PMID: 22409371]">Perera 2012</a>). Therefore, effective COPD management should aim to relieve presenting symptoms, prevent future exacerbations and delay disease progression (<a href="./references#CD013113-bbs2-0100" title="WoodruffPG , AgustiA , RocheN , SinghD , MartinezFJ . Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet2015;385(9979):1789-98. [PMID: 25943943]">Woodruff 2015</a>), with an emphasis on a comprehensive care plan for COPD and associated comorbidities (<a href="./references#CD013113-bbs2-0014" title="BarnesN , CalverleyPM , KaplanA , RabeKF . Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulmonary Medicine2013;13:54. [PMID: 23971625]">Barnes 2013</a>; <a href="./references#CD013113-bbs2-0097" title="WedzichaJA , BrillSE , AllinsonJP , DonaldsonGC . Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine2013;11:181. [PMID: 23945277]">Wedzicha 2013</a>). </p> <p>GOLD specifies the diagnostic criteria for COPD as a post bronchodilator forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio of less than 0.70 (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). However, defining COPD by these lung function test indices alone may imply that COPD is a homogenous condition. In fact, COPD is a heterogeneous group of conditions with a wide array of symptoms and therapeutic responses towards conventional treatment, and prognoses and comorbidities associated with COPD vary. This heterogeneity cannot be explained by lung function alone, and groups of people with COPD who express particular characteristics can be regarded as having different phenotypes (<a href="./references#CD013113-bbs2-0040" title="HanMK , AgustiA , CalverleyPM , CelliBR , CrinerG , CurtisJL , et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. American Journal of Respiratory and Critical Care Medicine2010;182(5):598-604. [PMID: 20522794]">Han 2010</a>). The ultimate goal of identifying COPD phenotypes is to develop effective and people‐oriented treatment regimens, in order to improve clinical outcomes. </p> <p>People experiencing two or more exacerbations of COPD per year are regarded as having frequent exacerbations (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>); people who experienced frequent exacerbations in the past often have a progressive decline in lung function and a poorer prognosis (<a href="./references#CD013113-bbs2-0086" title="SeemungalTA , DonaldsonGC , PaulEA , BestallJC , JeffriesDJ , WedzichaJA . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(5 Pt 1):1418-22. [PMID: 9603117]">Seemungal 1998</a>). The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study has shown that the strongest predictor of frequent COPD exacerbations in the future is the number of exacerbations experienced in the previous year (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>). </p> <p>In addition, people with frequent exacerbations tend to be more susceptible to viral infections (<a href="./references#CD013113-bbs2-0097" title="WedzichaJA , BrillSE , AllinsonJP , DonaldsonGC . Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine2013;11:181. [PMID: 23945277]">Wedzicha 2013</a>). In other words, a management strategy that includes virus infection as a treatment target may be effective for people who repeatedly experience COPD exacerbations. Furthermore, some studies suggest that GERD, a disease comprising symptoms, end‐organ effects and complications related to the reflux of gastric contents into the oesophagus, oral cavity or the lung (<a href="./references#CD013113-bbs2-0057" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology2013;108(3):308-28. [PMID: 23419381]">Katz 2013</a>), is an independent predictor of frequent COPD exacerbations (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>; <a href="./references#CD013113-bbs2-0049" title="IngebrigtsenTS , MarottJL , VestboJ , NordestgaardBG , HallasJ , LangeP . Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology2015;20(1):101-7. [PMID: 25297724]">Ingebrigtsen 2015</a>; <a href="./references#CD013113-bbs2-0063" title="MartinezCH , OkajimaY , MurrayS , WashkoGR , MartinezFJ , SilvermanEK , et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respiratory Research2014;15:62. [PMID: 24894541]">Martinez 2014</a>; <a href="./references#CD013113-bbs2-0092" title="TeradaK , MuroS , SatoS , OharaT , HarunaA , MarumoS , et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax2008;63(11):951-5. [PMID: 18535116]">Terada 2008</a>). It is worth highlighting that the relative risk (RR) of an exacerbation over two years in people with COPD and GERD is 1.93 (95% confidence interval (CI): 1.32 to 2.84), i.e. the risk of exacerbation is almost twice as high for people who have GERD (<a href="./references#CD013113-bbs2-0092" title="TeradaK , MuroS , SatoS , OharaT , HarunaA , MarumoS , et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax2008;63(11):951-5. [PMID: 18535116]">Terada 2008</a>). </p> <p>As a common condition, the diagnosis of GERD is often made by general practitioners and gastroenterologists in outpatients departments (<a href="./references#CD013113-bbs2-0088" title="ShaheenNJ , HansenRA , MorganDR , GangarosaLM , RingelY , ThinyMT , et al. The burden of gastrointestinal and liver diseases, 2006. American Journal of Gastroenterology2006;101(9):2128-38. [PMID: 16848807]">Shaheen 2006</a>). Prevalence of GERD is rising worldwide, and the associated disease burden is also increasing (<a href="./references#CD013113-bbs2-0028" title="El-SeragHB , SweetS , WinchesterCC , DentJ . Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut2014;63(6):871-80. [PMID: 23853213]">El‐Serag 2014</a>). For instance, cumulative incidence of pneumonia has been reported to be significantly higher in people with GERD than in people without GERD (<a href="./references#CD013113-bbs2-0043" title="HsuWT , LaiCC , WangYH , TsengPH , WangK , WangCY , et al. Risk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort study. PLoS ONE2017;12(8):e0183808. [DOI: 10.1371/journal.pone.0183808] [PMID: 28837700]">Hsu 2017</a>). Microaspiration of gastric acid tends to occur in people with GERD, and it has been suggested that this condition is pathologically connected to the development of lung diseases (<a href="./references#CD013113-bbs2-0069" title="MoreheadRS . Gastro-oesophageal reflux disease and non-asthma lung disease. European Respiratory Review2009;18(114):233-43. [PMID: 20956148]">Morehead 2009</a>). <a href="./references#CD013113-bbs2-0043" title="HsuWT , LaiCC , WangYH , TsengPH , WangK , WangCY , et al. Risk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort study. PLoS ONE2017;12(8):e0183808. [DOI: 10.1371/journal.pone.0183808] [PMID: 28837700]">Hsu 2017</a> reported that the use of proton pump inhibitors (PPIs), a pharmacological treatment for GERD, for more than four months increased the risk of pneumonia in people with GERD. A potential explanation of the relationship between PPI and pneumonia is that an increase in pH due to gastric acid suppression might promote bacterial colonization in the oral cavity, which subsequently leads to pneumonia (<a href="./references#CD013113-bbs2-0038" title="GulmezSE , HolmA , FrederiksenH , JensenTG , PedersenC , HallasJ . Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine2007;167(9):950-5. [PMID: 17502537]">Gulmez 2007</a>). However, the precise mechanism of the development of pneumonia when using PPIs is still unclear. </p> <p>The cause of GERD is complex, but there are several known factors. First, gastric reflux occurs when the gradient of pressure between the stomach and the lower oesophageal sphincter is lost, due to low or absent lower oesophageal sphincter pressure and anatomic disruptions of the oesophagogastric junction, such as hiatal hernia (<a href="./references#CD013113-bbs2-0071" title="OrlandoRC . Overview of the mechanisms of gastroesophageal reflux. American Journal of Medicine2001;111(Suppl 8A):174S-7S. [PMID: 11749946]">Orlando 2001</a>). Second, oesophageal peristaltic dysfunction (dysfunction of oesophageal contraction movement which eliminates oesophageal contents to the stomach) and prolonged oesophageal acid clearance (a dysfunction of eliminating contents in the oesophagus by the oesophageal contraction movement, secretions from the oesophagus glands or swallowed saliva) can feature in gastroesophageal reflux (<a href="./references#CD013113-bbs2-0056" title="KahrilasPJ , DoddsWJ , HoganWJ . Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology1988;94(1):73-80. [PMID: 3335301]">Kahrilas 1988</a>; <a href="./references#CD013113-bbs2-0091" title="SugiuraT , IwakiriK , KotoyoriM , KobayashiM . Relationship between severity of reflux esophagitis according to the Los Angeles classification and esophageal motility. Journal of Gastroenterology2001;36(4):226-30. [PMID: 11324724]">Sugiura 2001</a>). Amongst people with COPD who smoke, nicotine might lead to changes in lower oesophageal sphincter pressure and abnormal oesophageal peristalsis (<a href="./references#CD013113-bbs2-0073" title="PandolfinoJE , KahrilasPJ . Smoking and gastro-oesophageal reflux disease. European Journal of Gastroenterology and Hepatology2000;12(8):837-42. [PMID: 10958210]">Pandolfino 2000</a>). Third, certain pharmacological therapies for COPD, including theophylline, beta<sub>2</sub>‐agonists, anticholinergics, and corticosteroids, may alter oesophageal sphincter tone and respiratory mechanics, leading to worsened symptoms of GERD (<a href="./references#CD013113-bbs2-0075" title="PhulpotoMA , QayyumS , RizviN , KhuhawarSM . Proportion of gastroesophageal reflux symptoms in patients with chronic obstructive pulmonary disease. Journal of the Pakistan Medical Association2005;55(7):276-9. [PMID: 16108509]">Phulpoto 2005</a>). GERD has been reported to be a frequent comorbidity of COPD, and prevalence of GERD has been found to be higher in people with COPD compared with healthy controls (<a href="./references#CD013113-bbs2-0023" title="CasanovaC , BaudetJS , delValle VelascoM , MartinJM , Aguirre-JaimeA , deTorresJP , et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. European Respiratory Journal2004;23(6):841-5. [PMID: 15218995]">Casanova 2004</a>; <a href="./references#CD013113-bbs2-0068" title="MokhlesiB , MorrisAL , HuangCF , CurcioAJ , BarrettTA , KampDW . Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest2001;119(4):1043-8. [PMID: 11296167]">Mokhlesi 2001</a>). Fourth, the prevalence of GERD symptoms tends to be higher in people with severe airway obstruction (<a href="./references#CD013113-bbs2-0068" title="MokhlesiB , MorrisAL , HuangCF , CurcioAJ , BarrettTA , KampDW . Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest2001;119(4):1043-8. [PMID: 11296167]">Mokhlesi 2001</a>). Lung hyperinflation correlates with COPD severity and requires more inspiratory effort to inhale. This altered mechanism of breathing may increase the transdiaphragmatic pressure gradient on the chest and abdomen, and lead to GERD (<a href="./references#CD013113-bbs2-0027" title="Del GrandeLM , HerbellaFA , BigataoAM , AbraoH , JardimJR , PattiMG . Pathophysiology of gastroesophageal reflux in patients with chronic pulmonary obstructive disease Is linked to an increased transdiaphragmatic pressure gradient and not to a defective esophagogastric barrier. Journal of Gastrointestinal Surgery2016;20(1):104-10. [PMID: 26403715]">Del Grande 2016</a>). Thus, it may also explain the correlation between severe COPD and GERD. Other factors, such as obesity and comorbidities, may also be associated with the increased prevalence of GERD found in people with COPD (<a href="./references#CD013113-bbs2-0041" title="HerbellaFA , PattiMG . Gastroesophageal reflux disease: from pathophysiology to treatment. World Journal of Gastroenterology2010;16(30):3745-9. [PMID: 20698035]">Herbella 2010</a>). </p> <p>The prevalence of GERD in people with COPD has been reported to range from 17% to 78% (<a href="./references#CD013113-bbs2-0060" title="LeeAL , GoldsteinRS . Gastroesophageal reflux disease in COPD: links and risks. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1935-49. [PMID: 26392769]">Lee 2015</a>). The mechanism underlying GERD that leads to COPD exacerbations is thought to be related to pulmonary microaspiration of gastric acid into airways (<a href="./references#CD013113-bbs2-0053" title="JavorkovaN , VarechovaS , PecovaR , TatarM , BalazD , DemeterM , et al. Acidification of the oesophagus acutely increases the cough sensitivity in patients with gastro-oesophageal reflux and chronic cough. Neurogastroenterology and Motility2008;20(2):119-24. [PMID: 17999650]">Javorkova 2008</a>; <a href="./references#CD013113-bbs2-0060" title="LeeAL , GoldsteinRS . Gastroesophageal reflux disease in COPD: links and risks. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1935-49. [PMID: 26392769]">Lee 2015</a>), and this mechanism is also thought to be a risk factor for pneumonia (<a href="./references#CD013113-bbs2-0033" title="GaudeGS . Pulmonary manifestations of gastroesophageal reflux disease. Annals of Thoracic Medicine2009;4(3):115-23. [PMID: 19641641]">Gaude 2009</a>; <a href="./references#CD013113-bbs2-0092" title="TeradaK , MuroS , SatoS , OharaT , HarunaA , MarumoS , et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax2008;63(11):951-5. [PMID: 18535116]">Terada 2008</a>). The inflammatory response triggered by GERD may cause the contraction of airways via vagal reflex or further stimulate acid sensitive receptors in the oesophageal wall, both of which may lead to COPD exacerbations (<a href="./references#CD013113-bbs2-0062" title="MansfieldLE , HameisterHH , SpauldingHS , SmithNJ , GlabN . The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention. Annals of Allergy1981;47(6):431-4. [PMID: 7325414]">Mansfield 1981</a>; <a href="./references#CD013113-bbs2-0083" title="SchanCA , HardingSM , HaileJM , BradleyLA , RichterJE . Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology. Chest1994;106(3):731-7. [PMID: 8082350]">Schan 1994</a>; <a href="./references#CD013113-bbs2-0093" title="TuchmanDN , BoyleJT , PackAI , ScwartzJ , KokonosM , SpitzerAR , et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology1984;87(4):872-81. [PMID: 6468875]">Tuchman 1984</a>). Furthermore, GERD is considered to be one of the causes of chronic cough, which is a common symptom of COPD (<a href="./references#CD013113-bbs2-0050" title="IrwinRS , MadisonJM . The diagnosis and treatment of cough. New England Journal of Medicine2000;343(23):1715-21. [PMID: 11106722]">Irwin 2000</a>). </p> </section> <section id="CD013113-sec-0011"> <h3 class="title" id="CD013113-sec-0011">Description of the intervention</h3> <p>PPIs are one of the most effective medications for reducing gastric acid secretion. Since their introduction in the late 1980s, PPIs remain one of the most commonly prescribed medications worldwide (<a href="./references#CD013113-bbs2-0015" title="BashfordJN , NorwoodJ , ChapmanSR . Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ1998;317(7156):452-6. [PMID: 9703528]">Bashford 1998</a>). Currently, seven PPIs are available (lansoprazole, omeprazole, pantoprazole, rabeprazole, esomeprazole, dexlansoprazole, and vonoprazan), and some are available as over‐the‐counter medications. Vonoprazan is a novel PPI and has been licensed for use to treat GERD in Japan since 2015. In the USA, for example, lansoprazole, omeprazole and esomeprazole do not require prescription, and omeprazole can be purchased in high‐street supermarkets. However, pantoprazole, rabeprazole, and dexlansoprazole are all prescription‐only medications (<a href="./references#CD013113-bbs2-0024" title="ChenJ , BradyP . Gastroesophageal reflux disease: pathophysiology, diagnosis, and treatment. Gastroenterology Nursing2019;42(1):20-8. [PMID: 30688703]">Chen 2019</a>). In Japan, all PPIs require a prescription. Therefore, consumer usage of PPIs varies from country to country. Nevertheless, PPIs are one of the most prescribed and most consumed medications worldwide. </p> <p>The family of PPIs has dramatically improved many conditions, such as peptic ulcer disease, as well as being used in the treatment and prevention of gastroduodenal ulcers associated with the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) (<a href="./references#CD013113-bbs2-0010" title="AgrawalNM , CampbellDR , SafdiMA , LukasikNL , HuangB , HaberMM . Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Archives of Internal Medicine2000;160(10):1455-61. [PMID: 10826458]">Agrawal 2000</a>; <a href="./references#CD013113-bbs2-0080" title="RostomA , DubeC , WellsG , TugwellP , WelchV , JolicoeurE , et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD002296. [DOI: 10.1002/14651858.CD002296]">Rostom 2002</a>). They are also included in regimens that aim to eradicate <i>Helicobacter pylori</i> (<a href="./references#CD013113-bbs2-0044" title="HuY , ZhuY , LuNH . Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Frontiers in Cellular and Infection Microbiology2017;7:168. [PMID: 28529929]">Hu 2017</a>). In the longer‐term, PPIs can prevent pulmonary microaspiration of gastric contents by reducing the production of stomach acid (<a href="./references#CD013113-bbs2-0060" title="LeeAL , GoldsteinRS . Gastroesophageal reflux disease in COPD: links and risks. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1935-49. [PMID: 26392769]">Lee 2015</a>). PPIs also promote the healing of oesophageal erosion produced by the reflux of gastric acid into the oesophagus (<a href="./references#CD013113-bbs2-0026" title="DekelR , MorseC , FassR . The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs2004;64(3):277-95. [PMID: 14871170]">Dekel 2004</a>). </p> <p>Treatment with PPIs remains the mainstay approach to the management of GERD (<a href="./references#CD013113-bbs2-0032" title="FreedbergDE , KimLS , YangYX . The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology2017;152(4):706-15. [DOI: 10.1053/j.gastro.2017.01.031] [PMID: 28257716]">Freedberg 2017</a>; <a href="./references#CD013113-bbs2-0057" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology2013;108(3):308-28. [PMID: 23419381]">Katz 2013</a>). Given that GERD is an independent risk factor for frequent exacerbations of COPD (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>), <a href="./references#CD013113-bbs2-0016" title="BaumelerL , PapakonstantinouE , MilenkovicB , LacomaA , LouisR , AertsJG , et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology2016;21(5):883-90. [PMID: 26970108]">Baumeler 2016</a> hypothesised that administration of PPIs for GERD might improve the symptoms and frequency of acute exacerbations of COPD. However, this study eventually showed that annual COPD exacerbation rates and severity were higher amongst participants in the PPI group than in those participants who were not receiving PPI. Moreover, in the PPI group, the incidence rates of hypertension, heart failure, diabetes mellitus and dementia were higher and the quality of life was lower than in the non‐PPI group (<a href="./references#CD013113-bbs2-0016" title="BaumelerL , PapakonstantinouE , MilenkovicB , LacomaA , LouisR , AertsJG , et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology2016;21(5):883-90. [PMID: 26970108]">Baumeler 2016</a>). </p> <p>The following reasons might partly explain why the effects of PPI on COPD are different from Baumeler's hypothesis that PPI might reduce COPD exacerbations (<a href="./references#CD013113-bbs2-0016" title="BaumelerL , PapakonstantinouE , MilenkovicB , LacomaA , LouisR , AertsJG , et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology2016;21(5):883-90. [PMID: 26970108]">Baumeler 2016</a>); (1) the effect of PPIs on bacterial infection; (2) the influence of confounding factors; and (3) other effects of PPIs. </p> <p>First, as gastric acid secretion plays a protective role against infectious agents, prolonged PPI‐induced low acid status can increase the risk of bacterial overgrowth in the stomach and oesophagus (<a href="./references#CD013113-bbs2-0029" title="EomCS , JeonCY , LimJW , ChoEG , ParkSM , LeeKS . Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. Canadian Medical Association Journal2011;183(3):310-9. [PMID: 21173070]">Eom 2011</a>). This bacterial overgrowth caused by long‐term PPI use may heighten the risk of bacterial aspiration (<a href="./references#CD013113-bbs2-0033" title="GaudeGS . Pulmonary manifestations of gastroesophageal reflux disease. Annals of Thoracic Medicine2009;4(3):115-23. [PMID: 19641641]">Gaude 2009</a>). It may also be associated with an increased risk of community‐acquired pneumonia (CAP) (<a href="./references#CD013113-bbs2-0058" title="LaheijRJ , SturkenboomMC , HassingRJ , DielemanJ , StrickerBH , JansenJB . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association2004;292(16):1955-60. [PMID: 15507580]">Laheij 2004</a>). CAP is a type of pneumonia caused by organisms found regularly outside of hospital settings, such as <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Mycoplasma</i>, as opposed to hospital‐acquired pneumonia (<a href="./references#CD013113-bbs2-0066" title="MetlayJP , WatererGW , LongAC , AnzuetoA , BrozekJ , CrothersK , et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine2019;200(7):e45-67. [PMID: 31573350]">Metlay 2019</a>). </p> <p>Observational studies have shown a positive association between PPI usage and CAP (<a href="./references#CD013113-bbs2-0038" title="GulmezSE , HolmA , FrederiksenH , JensenTG , PedersenC , HallasJ . Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine2007;167(9):950-5. [PMID: 17502537]">Gulmez 2007</a>; <a href="./references#CD013113-bbs2-0058" title="LaheijRJ , SturkenboomMC , HassingRJ , DielemanJ , StrickerBH , JansenJB . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association2004;292(16):1955-60. [PMID: 15507580]">Laheij 2004</a>). In a large‐scale population‐based cohort study derived from the Clinical Practice Research Datalink, <a href="./references#CD013113-bbs2-0021" title="BraekenDC , RohdeGG , FranssenFM , DriessenJH , vanStaaTP , SouvereinPC , et al. Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2425-32. [PMID: 28860737]">Braeken 2017</a> indicated that people with COPD were at a four‐hold increased risk of developing CAP (hazard ratio 4.51, 95% confidence interval (CI): 4.27 to 4.77). </p> <p>Several meta‐analyses have suggested that short duration of PPI usage, particularly within the first month, may associated with an increased risk of CAP (<a href="./references#CD013113-bbs2-0035" title="GiulianoC , WilhelmSM , Kale-PradhanPB . Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Review of Clinical Pharmacology2012;5(3):337-44. [PMID: 22697595]">Giuliano 2012</a>; <a href="./references#CD013113-bbs2-0055" title="JohnstoneJ , NerenbergK , LoebM . Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Alimentary Pharmacology and Therapeutics2010;31(11):1165-77. [PMID: 20222914]">Johnstone 2010</a>; <a href="./references#CD013113-bbs2-0059" title="LambertAA , LamJO , PaikJJ , Ugarte-GilC , DrummondMB , CrowellTA . Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE2015;10(6):e0128004. [DOI: 10.1371/journal.pone.0128004] [PMID: 26042842]">Lambert 2015</a>). However, it is not yet clear why short‐duration usage of PPIs correlates with increased risk of CAP. In addition, people with COPD and CAP were found to have longer hospital stays and mortality rates when compared to people with CAP alone (<a href="./references#CD013113-bbs2-0020" title="BraekenDC , FranssenFM , SchutteH , PletzMW , BalsR , MartusP , et al. Increased severity and mortality of CAP in COPD: results from the German Competence Network, CAPNETZ. Journal of the COPD Foundation2015;2(2):131-40. [PMID: 28848837]">Braeken 2015</a>). Thus, it is likely that the increased risk of CAP associated with PPI treatment could eventually lead to further COPD exacerbations. </p> <p>Second, there are few intervention studies on this topic, and association of confounding factors may be unclear and controversial. As stated previously, studies have suggested that PPI usage may increase the risk of CAP (<a href="./references#CD013113-bbs2-0038" title="GulmezSE , HolmA , FrederiksenH , JensenTG , PedersenC , HallasJ . Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine2007;167(9):950-5. [PMID: 17502537]">Gulmez 2007</a>; <a href="./references#CD013113-bbs2-0058" title="LaheijRJ , SturkenboomMC , HassingRJ , DielemanJ , StrickerBH , JansenJB . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association2004;292(16):1955-60. [PMID: 15507580]">Laheij 2004</a>). By contrast, other studies have suggested that this associated risk may be due to significant unmeasured confounding (e.g. comorbidities and baseline characteristics) (<a href="./references#CD013113-bbs2-0054" title="JenaAB , SunE , GoldmanDP . Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. Journal of General Internal Medicine2013;28(2):223-30. [PMID: 22956446]">Jena 2013</a>; <a href="./references#CD013113-bbs2-0072" title="OthmanF , CrooksCJ , CardTR . Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ2016;355:i5813. [PMID: 28715344]">Othman 2016</a>). <a href="./references#CD013113-bbs2-0072" title="OthmanF , CrooksCJ , CardTR . Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ2016;355:i5813. [PMID: 28715344]">Othman 2016</a> examined 160,000 new PPI users to investigate whether there was a change in the risk of CAP before and after the prescription of PPIs. This cohort study initially showed that the risk of CAP was higher in those prescribed PPI (RR 1.67, 95% CI 1.55 to 1.79). However, after adjustment for confounding factors, PPI use was associated with a lower risk of CAP (RR 0.91, 95% CI 0.83 to 0.99). Thus, the association between PPI usage and risk of CAP may be due to confounding factors. </p> <p>Third, PPI may have effects other than acid suppression. <a href="./references#CD013113-bbs2-0065" title="MeijvisSC , CornipsMC , VoornGP , SouvereinPC , EndemanH , BiesmaDH , et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. The European Respiratory Journal2011;38(5):1165-72. [PMID: 21478217]">Meijvis 2011</a> suggested that PPIs may not increase either the gastrointestinal or oropharyngeal bacteria that cause CAP (<a href="./references#CD013113-bbs2-0065" title="MeijvisSC , CornipsMC , VoornGP , SouvereinPC , EndemanH , BiesmaDH , et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. The European Respiratory Journal2011;38(5):1165-72. [PMID: 21478217]">Meijvis 2011</a>). One possible explanation for COPD exacerbation, besides bacterial infections, could be the effects of PPIs on viral infections. </p> <p>As well as bacterial infections, several viruses (such as the human rhinovirus) have been reported to be associated with exacerbations of COPD (<a href="./references#CD013113-bbs2-0030" title="FalseyAR , FormicaMA , HennesseyPA , CriddleMM , CullenderWM , WalshEE . Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173(6):639-43. [PMID: 16387798]">Falsey 2006</a>; <a href="./references#CD013113-bbs2-0046" title="HurstJR , DonaldsonGC , WilkinsonTM , PereraWR , WedzichaJA . Epidemiological relationships between the common cold and exacerbation frequency in COPD. European Respiratory Journal2005;26(5):846-52. [PMID: 16264045]">Hurst 2005</a>). In previous studies, causes of COPD exacerbations were shown to be mostly bacterial infections, and viral infections were considered to be the cause of only 14% to 18% of COPD exacerbations (<a href="./references#CD013113-bbs2-0022" title="BuschoRO , SaxtanD , ShultzPS , FinchE , MufsonMA . Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. Journal of Infectious Diseases1978;137(4):377-83. [PMID: 206630]">Buscho 1978</a>; <a href="./references#CD013113-bbs2-0089" title="SmithCB , GoldenCA , KannerRE , Renzetti AD Jr. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. American Review of Respiratory Disease1980;121(2):225-32. [PMID: 6244766]">Smith 1980</a>). However, with the widespread use of pneumococcal vaccines worldwide, the general microbial pathogenesis pathway is likely to have changed and as such, awareness of virus infections in the prognosis of people with COPD is increasing (<a href="./references#CD013113-bbs2-0066" title="MetlayJP , WatererGW , LongAC , AnzuetoA , BrozekJ , CrothersK , et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine2019;200(7):e45-67. [PMID: 31573350]">Metlay 2019</a>). Virus detection during COPD exacerbation has been found to vary from 22% to 60% (<a href="./references#CD013113-bbs2-0039" title="GunawardanaN , FinneyL , JohnstonSL , MalliaP . Experimental rhinovirus infection in COPD: implications for antiviral therapies. Antiviral Research2014;102:95-105. [PMID: 24370732]">Gunawardana 2014</a>; <a href="./references#CD013113-bbs2-0087" title="SethiS , MurphyTF . Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(22):2355-65. [PMID: 19038881]">Sethi 2008</a>). Rhinoviruses are the most reported virus in many studies, with influenza and respiratory syncytial viruses also commonly detected. Other existing data also support a causal link between viral infections and exacerbations of COPD (<a href="./references#CD013113-bbs2-0017" title="BeasleyV , JoshiPV , SinganayagamA , MolyneauxPL , JohnstonSL , MalliaP . Lung microbiology and exacerbations in COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:555-69. [PMID: 22969296]">Beasley 2012</a>; <a href="./references#CD013113-bbs2-0078" title="QuintJK , DonaldsonGC , GoldringJJ , Baghai-RavaryR , HurstJR , WedzichaJA . Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest2010;137(4):812-22. [PMID: 19837822]">Quint 2010</a>; <a href="./references#CD013113-bbs2-0097" title="WedzichaJA , BrillSE , AllinsonJP , DonaldsonGC . Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine2013;11:181. [PMID: 23945277]">Wedzicha 2013</a>). <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> suggested a possible preventive effect of PPIs against viral infection, and an association with a reduction in COPD exacerbations. This inhibitory effect of PPIs on viral infection could not explain why Baumeler's hypothesis was not completely supported. The efficacy and safety of PPIs in relation to viral infection is still unclear. </p> <p>Therefore, the effects of PPIs on acute exacerbations of COPD are not yet clear and remain controversial (<a href="./references#CD013113-bbs2-0031" title="FilionKB , ChateauD , TargownikLE , GershonA , DurandM , TamimH , et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut2014;63(4):552-8. [PMID: 23856153]">Filion 2014</a>). </p> <section id="CD013113-sec-0012"> <h4 class="title">Usual therapy for COPD</h4> <p>Updated GOLD guidelines and recently published clinical recommendations by the American Thoracic Society (ATS)/European Respiratory Society (ERS) have emphasised the benefits of smoking cessation and pharmacological therapy, including β2‐agonists, anticholinergics, and corticosteroids (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>; <a href="./references#CD013113-bbs2-0098" title="Wedzicha JA (ERS Co-Chair), MiravitllesM , HurstJR , CalverleyPM , AlbertRK , AnzuetoA , et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. The European Respiratory Journal2017;49(3):1600791. [DOI: 10.1183/13993003.00791-2016.] [PMID: 28298398]">Wedzicha 2017</a>). The most appropriate pharmacological therapies should be selected for each person, according to their severity of COPD and symptoms. Asymptomatic people with mild airflow limitation can be treated with on‐demand short‐acting bronchodilators, such as inhalation of short‐acting beta2‐agonists (SABA) or short‐acting muscarinic antagonists (SAMA). If the symptoms do not improve, long‐acting beta‐agonists (LABA), long‐acting muscarinic antagonists (LAMA), and inhaled corticosteroids are also used. If LABA or LAMA monotherapy cannot control the symptoms, administration of two or more medications may be effective (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). Furthermore, non‐pharmacological therapies for COPD are also considered, including education and self‐management, smoking cessation, nutritional guidance, pulmonary rehabilitation, immunisations, and long‐term oxygen therapy (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). To prevent acute exacerbation of COPD, it is also necessary to combine pharmacological approaches with non‐pharmacological therapies. GOLD guidelines suggest that the therapeutic goal in terms of COPD exacerbation is to minimise the adverse effects on physical symptoms, respiratory function, and quality of life associated with acute exacerbations (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). Among several COPD clinical phenotypes, the adverse impact of frequent exacerbations is substantial. Due to this, the management strategy for acute exacerbations of COPD should be guided by phenotype (<a href="./references#CD013113-bbs2-0011" title="AgustiA , BelE , ThomasM , VogelmeierC , BrusselleG , HolgateS , et al. Treatable traits: toward precision medicine of chronic airway diseases. The European Respiratory Journal2016;47(2):410-9. [PMID: 26828055]">Agusti 2016</a>). </p> </section> </section> <section id="CD013113-sec-0013"> <h3 class="title" id="CD013113-sec-0013">How the intervention might work</h3> <p>It has been suggested that GERD could be an independent risk factor of COPD exacerbation (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>). The acid suppression effects of PPIs might play a role in COPD management based on the following mechanisms. Gastric acid secretion is a complex process regulated by at least three types of receptors on the parietal cells (histamine, gastrin, and acetylcholine). Usually, PPIs reduce gastric acid production by irreversibly blocking the enzymes responsible for hydrogen potassium ATPase (proton pump) in parietal cells (<a href="./references#CD013113-bbs2-0012" title="AkazawaY , FukudaD , FukudaY . Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therapeutic Advances in Gastroenterology2016;9(6):845-52. [PMID: 27803739]">Akazawa 2016</a>; <a href="./references#CD013113-bbs2-0085" title="ScottDR , MunsonKB , MarcusEA , LambrechtNW , SachsG . The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Alimentary Pharmacology and Therapeutics2015;42(11-2):1315-26. [PMID: 26423447]">Scott 2015</a>). However, vonoprazan has a somewhat unique action, which involves reversibly blocking hydrogen potassium ATPase through competing with potassium ions (<a href="./references#CD013113-bbs2-0045" title="HuntRH , ScarpignatoC . Potassium-Competitive Acid Blockers (P-CABs): are they finally ready for prime time in acid-related disease?Clinical and Translational Gastroenterology2015;6:e119. [PMID: 26513137]">Hunt 2015</a>). Thus, vonoprazan is a faster‐acting acid suppressive agent than conventional PPIs. Although vonoprazan differs somewhat from the existing PPIs, it is still classified as a PPI because it inhibits the proton pump and suppresses gastric acid production. PPIs, including vonoprazan, make it possible to reduce gastric acid secretion and to prevent central reflex and pulmonary microaspiration of stomach acid (<a href="./references#CD013113-bbs2-0060" title="LeeAL , GoldsteinRS . Gastroesophageal reflux disease in COPD: links and risks. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1935-49. [PMID: 26392769]">Lee 2015</a>). However, PPIs can cause gastric and oesophagus bacterial overgrowth by excessive acid suppression (<a href="./references#CD013113-bbs2-0029" title="EomCS , JeonCY , LimJW , ChoEG , ParkSM , LeeKS . Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. Canadian Medical Association Journal2011;183(3):310-9. [PMID: 21173070]">Eom 2011</a>), and may lead to COPD exacerbation (<a href="./references#CD013113-bbs2-0035" title="GiulianoC , WilhelmSM , Kale-PradhanPB . Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Review of Clinical Pharmacology2012;5(3):337-44. [PMID: 22697595]">Giuliano 2012</a>; <a href="./references#CD013113-bbs2-0058" title="LaheijRJ , SturkenboomMC , HassingRJ , DielemanJ , StrickerBH , JansenJB . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association2004;292(16):1955-60. [PMID: 15507580]">Laheij 2004</a>; <a href="./references#CD013113-bbs2-0059" title="LambertAA , LamJO , PaikJJ , Ugarte-GilC , DrummondMB , CrowellTA . Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE2015;10(6):e0128004. [DOI: 10.1371/journal.pone.0128004] [PMID: 26042842]">Lambert 2015</a>). The same safety concerns have also been discussed regarding vonoprazan (<a href="./references#CD013113-bbs2-0090" title="SuganoK . Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therapeutic Advances in Gastroenterology2018;11:1756283X17745776. [PMID: 29383028]">Sugano 2018</a>). In addition, excessive suppression of gastric acid increases the likelihood of developing CAP (<a href="./references#CD013113-bbs2-0038" title="GulmezSE , HolmA , FrederiksenH , JensenTG , PedersenC , HallasJ . Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine2007;167(9):950-5. [PMID: 17502537]">Gulmez 2007</a>; <a href="./references#CD013113-bbs2-0058" title="LaheijRJ , SturkenboomMC , HassingRJ , DielemanJ , StrickerBH , JansenJB . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association2004;292(16):1955-60. [PMID: 15507580]">Laheij 2004</a>), which may lead to worsening of COPD. Therefore, the relationship between the acid suppression effects of PPIs and COPD exacerbations remains controversial. </p> <p>In addition to acid suppression, PPIs have been reported to have an impact on viral infections, for example rhinovirus infections (<a href="./references#CD013113-bbs2-0061" title="LongJ , WrightE , MolestiE , TempertonN , BarclayW . Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research2015;4:30. [PMID: 26069727]">Long 2015</a>; <a href="./references#CD013113-bbs2-0081" title="SasakiT , YamayaM , YasudaH , InoueD , YamadaM , KuboH , et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. European Journal of Pharmacology2005;509(2-3):201-10. [PMID: 15733557]">Sasaki 2005</a>). Rhinoviruses are commonly identified viruses in people who experience frequent COPD exacerbations (<a href="./references#CD013113-bbs2-0046" title="HurstJR , DonaldsonGC , WilkinsonTM , PereraWR , WedzichaJA . Epidemiological relationships between the common cold and exacerbation frequency in COPD. European Respiratory Journal2005;26(5):846-52. [PMID: 16264045]">Hurst 2005</a>). A rhinovirus can amplify the expression of intercellular adhesion molecule‐1 (ICAM‐1) and cytokine (<a href="./references#CD013113-bbs2-0101" title="YuLY , SunLN , ZhangXH , LiYQ , YuL , YuanZQ , et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Advances in Therapy2017;34(5):1070-86. [PMID: 28429247]">Yu 2017</a>). ICAM‐1 is the major rhinovirus infection receptor and increases viral susceptibility on respiratory epithelial cells (<a href="./references#CD013113-bbs2-0034" title="GeorgeSN , GarchaDS , MackayAJ , PatelAR , SinghR , SapsfordRJ , et al. Human rhinovirus infection during naturally occurring COPD exacerbations. European Respiratory Journal2014;44(1):87-96. [PMID: 24627537]">George 2014</a>). Lansoprazole and omeprazole have been reported to have suppressing effects on the expression of ICAM‐1 (<a href="./references#CD013113-bbs2-0070" title="OharaT , ArakawaT . Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Digestive Diseases and Sciences1999;44(8):1710-5. [PMID: 10492157]">Ohara 1999</a>; <a href="./references#CD013113-bbs2-0096" title="WatanabeT , HiguchiK , TominagaK , FujiwaraY , ArakawaT . Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut2001;48(6):774-81. [PMID: 11358894]">Watanabe 2001</a>). Researchers found that both lansoprazole and omeprazole were able to suppress viral infections by inhibiting vacuolar hydrogen potassium ATPase, thereby increasing endosomal pH and inhibiting the expression of ICAM‐1 (<a href="./references#CD013113-bbs2-0081" title="SasakiT , YamayaM , YasudaH , InoueD , YamadaM , KuboH , et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. European Journal of Pharmacology2005;509(2-3):201-10. [PMID: 15733557]">Sasaki 2005</a>). Other studies have also suggested that PPIs may possess systemic anti‐inflammatory effects (<a href="./references#CD013113-bbs2-0018" title="BeckerJC , GrosserN , WaltkeC , SchulzS , ErdmannK , DomschkeW , et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochemical and Biophysical Research Communications2006;345(3):1014-21. [PMID: 16712795]">Becker 2006</a>; <a href="./references#CD013113-bbs2-0082" title="SasakiT , NakayamaK , YasudaH , YamayaM . A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Therapeutic Advances in Respiratory Disease2011;5(2):91-103. [PMID: 21285157]">Sasaki 2011</a>). Viral infections induce inflammatory mediators, including various cytokines (<a href="./references#CD013113-bbs2-0087" title="SethiS , MurphyTF . Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(22):2355-65. [PMID: 19038881]">Sethi 2008</a>). The anti‐inflammatory effect of PPIs is probably due to their effect of inhibiting the production of proinflammatory cytokines (<a href="./references#CD013113-bbs2-0082" title="SasakiT , NakayamaK , YasudaH , YamayaM . A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Therapeutic Advances in Respiratory Disease2011;5(2):91-103. [PMID: 21285157]">Sasaki 2011</a>). However, these antiviral and anti‐inflammatory effects of PPIs are primarily in vitro observations. Thus, evidence based on human studies is currently lacking. People who experience frequent COPD exacerbations may have a high sensitivity towards respiratory viral infections or have poor ability to prevent viral replications (<a href="./references#CD013113-bbs2-0034" title="GeorgeSN , GarchaDS , MackayAJ , PatelAR , SinghR , SapsfordRJ , et al. Human rhinovirus infection during naturally occurring COPD exacerbations. European Respiratory Journal2014;44(1):87-96. [PMID: 24627537]">George 2014</a>), which makes PPIs a viable treatment option for COPD. </p> </section> <section id="CD013113-sec-0014"> <h3 class="title" id="CD013113-sec-0014">Why it is important to do this review</h3> <p>COPD exacerbations are associated with substantial impact at both the individual level and for overall society (<a href="./references#CD013113-bbs2-0014" title="BarnesN , CalverleyPM , KaplanA , RabeKF . Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulmonary Medicine2013;13:54. [PMID: 23971625]">Barnes 2013</a>; <a href="./references#CD013113-bbs2-0097" title="WedzichaJA , BrillSE , AllinsonJP , DonaldsonGC . Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine2013;11:181. [PMID: 23945277]">Wedzicha 2013</a>). Therefore, effective management of existing COPD symptoms and prevention of exacerbations is a major therapeutic target. Given that the frequent‐exacerbation phenotype of COPD is known to be associated with a history of gastroesophageal reflux or heartburn (<a href="./references#CD013113-bbs2-0047" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [PMID: 20843247]">Hurst 2010</a>), PPIs may have the potential to influence COPD exacerbations. Since PPIs are widely available, with millions of users worldwide, it is necessary to evaluate the role of PPIs on people with COPD in this context. </p> <p>We have identified a randomised controlled trial (RCT) (<a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a>), and some other studies on this topic. To our knowledge, there is no existing systematic review that explores the precise role of PPIs in the management of COPD, so this remains to be ascertained. Therefore, a systematic review is necessary to determine whether PPIs are useful to treat people with COPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013113-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013113-sec-0015"></div> <p>To evaluate the efficacy and safety of PPI administration for people with COPD, focusing on COPD‐specific outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013113-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013113-sec-0016"></div> <section id="CD013113-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013113-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) in which participants were randomly assigned at the individual or cluster level. We included studies reported as full‐text articles, as abstracts/conference proceedings only, and unpublished data. We excluded cross‐over trials. </p> </section> <section id="CD013113-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included male and female adults aged 18 years or above with a diagnosis of COPD. We imposed no restrictions on clinical stability, i.e. people with stable COPD as well as those with exacerbated COPD were all eligible. We excluded participants who were prescribed PPIs within one month of study commencement. We also excluded studies that only included participants with asthma. For the purpose of this review, the definition of asthma was that defined by the study investigators (e.g. lack of substantial smoking history and significant bronchodilator reversibility). However, we acknowledged that certain studies might include participants with asthma‐COPD overlap syndrome (ACOS) i.e., people with chronic asthma that causes chronic airflow limitation (<a href="./references#CD013113-bbs2-0076" title="PostmaDS , RabeKF . The asthma-COPD overlap syndrome. New England Journal of Medicine2015;373(13):1241-9. [PMID: 26398072]">Postma 2015a</a>). Such asthma cases would be difficult to distinguish from COPD, so we decided to include studies of people with ACOS as well as studies that enrolled participants who were diagnosed with asthma as a COPD comorbidity. </p> <section id="CD013113-sec-0020"> <h5 class="title">Diagnosis</h5> <p>We included studies that enrolled participants diagnosed with COPD according to established criteria, such as the American Thoracic Society and GOLD criteria (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>). However, we recognised that the definition of any condition might change over time. For older studies, we examined the directness of the evidence by applying GRADE criteria to the diagnosis of the study participants, as determined by the investigators. If we identified trials in which only a subset of the participants had COPD, we included them on the basis that they reported disaggregated data by baseline diagnosis (COPD or asthma), or if the study investigators provided such data on request. </p> </section> <section id="CD013113-sec-0021"> <h5 class="title">Comorbidities</h5> <p>As long as the comorbidity itself was not the main focus of the study, we included studies that enrolled people with COPD and comorbid chronic physical conditions (e.g. hypertension, cardiovascular disease, GERD, asthma). We excluded participants with the following prespecified comorbidities: bronchiectasis or genetic diseases, such as cystic fibrosis or primary ciliary dyskinesia. </p> </section> <section id="CD013113-sec-0022"> <h5 class="title">Settings</h5> <p>All types of healthcare settings were eligible for inclusion: primary, secondary, and tertiary care. </p> </section> </section> <section id="CD013113-sec-0023"> <h4 class="title">Types of interventions</h4> <p>The optimal ("ideal") dosage regimen of oral PPIs has not been clarified. Standard dosage regimens of PPIs vary depending on the country/geographical location, but reference ranges have been reported as follows (<a href="./references#CD013113-bbs2-0052" title="IwakiriK , KinoshitaY , HabuY , OshimaT , ManabeN , FujiwaraY , et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. Journal of Gastroenterology2016;51(8):751-67. [PMID: 27325300]">Iwakiri 2016</a>; <a href="./references#CD013113-bbs2-0102" title="ZhangC , KwongJS , YuanRX , ChenH , XuC , WangYP , et al. Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD: network meta-analysis and GRADE system. Scientific Reports2017;7:41021. [PMID: 28102361]">Zhang 2017</a>). </p> <p> <ul id="CD013113-list-0001"> <li> <p>Standard dose of PPIs per day:</p> <ul id="CD013113-list-0002"> <li> <p>lansoprazole, 15 mg to 30 mg;</p> </li> <li> <p>omeprazole, 10 mg to 40 mg;</p> </li> <li> <p>pantoprazole, 40 mg;</p> </li> <li> <p>rabeprazole, 10 mg to 20 mg;</p> </li> <li> <p>esomeprazole, 10 mg to 20 mg;</p> </li> <li> <p>dexlansoprazole, 30 mg to 60 mg; and</p> </li> <li> <p>vonoprazan, 10 mg to 20 mg.</p> </li> </ul> </li> </ul> </p> <p>Eligible comparators were: placebo, usual care, or low‐dose PPI.</p> <p>We planned to consider the following comparisons.</p> <p> <ul id="CD013113-list-0003"> <li> <p>PPI plus usual COPD care versus placebo plus usual care.</p> </li> <li> <p>PPI plus usual COPD care versus usual care alone.</p> </li> <li> <p>PPI plus usual care versus lower‐dose PPI plus usual care.</p> </li> </ul> </p> <p>Our a priori definition of usual care for COPD was comprehensive respiratory care that aimed to support self‐management through drug treatment, regular exacerbation monitoring, lifestyle guidance on issues such as smoking cessation, vaccinations, nutritional advice, exercise therapy, and appropriate management of comorbidities. </p> <p>As it could take a few days for PPIs to exhibit their acid‐suppressive effects (<a href="./references#CD013113-bbs2-0013" title="AnderssonK , CarlssonE . Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacology and Therapeutics2005;108(3):294-307. [PMID: 16000224]">Andersson 2005</a>), and since chronic cough associated with GERD might take at least two to three months to develop (<a href="./references#CD013113-bbs2-0051" title="IrwinRS . Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest2006;129(1 Suppl):80S-94S. [PMID: 16428697]">Irwin 2006</a>), we included studies of at least two months' duration. We recorded and compared the intervention period and follow‐up duration. </p> </section> <section id="CD013113-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD013113-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013113-list-0004"> <li> <p>Exacerbations of COPD, reported as exacerbation rate or as time to first exacerbation after administration of PPIs </p> <ul id="CD013113-list-0005"> <li> <p>We extracted the definition used for an COPD exacerbation from the included study. If we had found the definition across studies to be inconsistent, we would have considered the impact on the overall result when applying GRADE ratings (<a href="./references#CD013113-bbs2-0042" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> </li> </ul> </li> <li> <p>Pneumonia and other serious adverse events (we planned to report pneumonia and other serious events separately) </p> <ul id="CD013113-list-0006"> <li> <p>Our definition of a serious adverse event follows that of established criteria, which is an untoward medical incident that leads to death, is life‐threatening, requires hospitalisation or prolongs existing hospitalisation, results in persistent or significant disability, a birth defect, or any important medical event that might jeopardise the participant or requires intervention to prevent its effects (<a href="./references#CD013113-bbs2-0048" title="International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Current Step 4 version dated 9 November 2016. //database.ich.org/sites/default/files/E6_R2_Addendum.pdf (accessed 5 July 2018).">ICH 2016</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013113-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013113-list-0007"> <li> <p>Quality of life (measured by a validated generic or disease‐specific tool for COPD)</p> </li> <li> <p>Lung function test indices: change from baseline in trough FEV<sub>1</sub> and FVC </p> </li> <li> <p>Acute respiratory infections (participants experiencing at least one episode)</p> </li> <li> <p>Disease‐specific adverse events (participants with at least one event)</p> </li> </ul> </p> </section> </section> </section> <section id="CD013113-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013113-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We identified studies from the Cochrane Airways Register of Trials (<a href="https://airways.cochrane.org/trials-register" target="_blank">airways.cochrane.org/trials-register</a>), which is a database maintained by the Group's Information Specialist. This register contains RCTs and quasi‐RCTs identified from several sources, including the following. </p> <p> <ul id="CD013113-list-0008"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL Issue 5, 2020) through Cochrane Register of Studies; </p> </li> <li> <p>Weekly searches of MEDLINE (Ovid SP) 1946 to present;</p> </li> <li> <p>Weekly searches of Embase (Ovid SP) 1974 to present;</p> </li> <li> <p>Monthly searches of PsycINFO (Ovid SP) 1967 to present;</p> </li> <li> <p>Monthly searches of CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EBSCO) 1937 to present; </p> </li> <li> <p>Monthly searches of AMED (Allied and Complementary Medicine) (EBSCO) from inception to present. </p> </li> </ul> </p> <p>Our literature search dated from database inception to 22 May 2020, with no restriction on language or publication status. Search strategies developed for the Cochrane Airways Register of Trials are illustrated in <a href="./appendices#CD013113-sec-0069">Appendix 1</a>. See <a href="./appendices#CD013113-sec-0075">Appendix 2</a> for search terms we used to identify studies for this review. </p> <p>We also searched the following trial registries on 22 May 2020.</p> <p> <ul id="CD013113-list-0009"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> </section> <section id="CD013113-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We performed handsearching of the conference proceedings of major conferences in the field of respiratory medicine (<a href="./appendices#CD013113-sec-0069">Appendix 1</a>). </p> <p>We checked the reference lists of all primary studies and relevant narrative review articles for additional references. We searched relevant manufacturers' websites for study information. </p> <p>We also monitored for errata or retractions of the included study on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> </section> </section> <section id="CD013113-sec-0030"> <h3 class="title" id="CD013113-sec-0030">Data collection and analysis</h3> <section id="CD013113-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SK and YT) independently screened the titles and abstracts of the search results and coded them as either 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We obtained full‐text study reports of all potentially eligible studies and two review authors (SK and HI) independently screened them for inclusion, recording the reasons for exclusion during the process. We resolved any disagreement through discussion or by consulting a third author (YT or TT). We identified and omitted duplicated reports and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We illustrated our selection process using a PRISMA flow diagram (<a href="./references#CD013113-bbs2-0067" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>). </p> </section> <section id="CD013113-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which was piloted for use on one study. One review author (SK) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD013113-list-0010"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: number (N), mean age, age range, gender, severity of COPD, diagnostic criteria, follow‐up duration, baseline lung function, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparator, concomitant medications, excluded medications, and dosage of the intervention. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding source(s), any notable conflicts of interest of trial authors and other information where available. </p> </li> </ul> </p> <p>Two review authors (SK and HI) independently extracted outcome data from included studies. We noted in the '<a href="./references#CD013113-sec-0085" title="">Characteristics of included studies</a>' table if the study authors did not report outcome data in a usable format. We resolved disagreements by consensus or by involving a third review author (YT). One review author (SK) then transferred data into the Review Manager software for further processing (<a href="./references#CD013113-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We checked that the data were entered correctly by undertaking double data entry and a second review author (HI) performed spot‐checks to assure accuracy of data extraction and management. </p> </section> <section id="CD013113-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SK and HI) independently assessed the risk of bias in included studies using Cochrane's 'Risk of bias' tool, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013113-bbs2-0042" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We resolved any disagreements by discussion or by involving a third review author (YT). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD013113-list-0011"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective outcome reporting (reporting bias)</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We judged each potential source of bias as either 'high', 'low', or 'unclear', and provided a quote from the study report with a justification for our judgement in the 'Risk of bias' table for each study. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for pneumonia or serious adverse events may be very different than that for a patient‐reported quality of life scale). Where information on risk of bias related to unpublished data or correspondence with a study author, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013113-sec-0034"> <h5 class="title">Assessment of bias in conducting this review</h5> <p>We conducted the review according to a published Cochrane protocol (<a href="./references#CD013113-bbs2-0103" title="KikuchiS , NaokiY , TajiriT , WatanabeN . Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD013113. [DOI: 10.1002/14651858.CD013113]">Kikuchi 2018</a>), and highlighted any deviations from it in the '<a href="#CD013113-sec-0083">Differences between protocol and review</a>' section. </p> </section> </section> <section id="CD013113-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to only undertake meta‐analysis when it was meaningful, i.e. if the treatments, participants, and the underlying clinical question were similar enough for data pooling. Since only one study was included, we reported our findings narratively. For transparency of data presentation, we also presented individual study findings as risk ratios (RRs) and means and standard deviations (SDs) or dichotomous and continuous data, respectively. </p> <p>For future updates of this review that include additional eligible studies, we plan to also calculate standardised mean differences (SMDs) for outcome data that are measured by different metric scales (for example, quality of life measured by different assessment tools). If we combine data from rating scales in such a meta‐analysis, we will ensure that we enter them with a consistent direction of effect (e.g. lower scores always indicate improvement). We will conduct an 'as reported' and intention‐to‐treat (ITT) analysis of the primary outcomes; for secondary outcomes we will use an 'as reported' analysis. </p> <p>For subsequent updates, we plan to describe skewed data narratively (for example, as medians and interquartile ranges for each group). </p> </section> <section id="CD013113-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>We used participants, rather than events, as the unit of analysis (i.e. number of participants admitted to hospital, rather than number of admissions per participant). If a study reported outcomes at multiple time points, we used the last time point measured. </p> <p>Where multiple trial arms are reported in an included study of future updates of this review, we will include only the relevant arms; similarly, if two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta‐analysis, we will either combine the active arms or divide the control group into halves to avoid double‐counting. </p> <p>We had planned to calculate risk ratios (for example, for the outcome of COPD exacerbation rates) should sufficient data be available, but we only identified one eligible study. For future updates of this review, we will analyse data on this basis, allowing for the inclusion of more than one event in a participant over the time of the trial. </p> <p>We also planned to analyse data from cluster‐RCTs if the trials had adjusted the data to account for clustering, or if we were able to adjust it ourselves. However, we did not identify any eligible cluster‐RCTs. Should future updates of this review include any cluster‐RCTs, we will manage data from these studies on this basis. </p> </section> <section id="CD013113-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we contacted investigators or study sponsors in order to verify/obtain key study characteristics or any missing outcome data. We did not conduct a meta‐analysis for this review because we had insufficient studies. </p> <p>For future updates, we intend to deal with missing participants using an ITT analysis, assuming that missing participants had failed treatment. In the case of dichotomous data that compared treatment response, we will include the total number of participants randomised to each comparison group (as the denominator). In the analyses of treatment response, we will only include data from trials that reported a group size prior to withdrawals. For continuous outcome measures, we plan to include summary statistics derived from mixed‐effect models, the last observation carried forward (LOCF), and observed cases' summary statistics. </p> <p>LOCF method is a standard methodology in many clinical fields for imputing incomplete data. However, LOCF can lead to an underestimation of standard errors, which increases the likelihood of finding a false positive result (<a href="./references#CD013113-bbs2-0064" title="MavridisD , SalantiG , FurukawaTA , CiprianiA , ChaimaniA , WhiteIR . Allowing for uncertainty due to missing and LOCF imputed outcomes in meta-analysis. Statistics in medicine2019;38(5):720-37. [PMID: 30347460]">Mavridis 2019</a>). Should additional studies be included in future updates of this review and a meta‐analysis performed, we also plan to investigate the impact of imputation by performing sensitivity analyses for each outcome. We can use a sensitivity analysis to check the robustness of results against departures from LOCF assumptions. </p> <p>Where missing data are thought to introduce serious bias, we will take this into consideration in the GRADE rating for affected outcomes. </p> </section> <section id="CD013113-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>Meta‐analysis was not feasible for this current review due to insufficient data. For future updates, we will use the Chi<sup>2</sup> test (P value of less than 0.10 to be indicative of statistical heterogeneity) and the I<sup>2</sup> statistic to assess statistical heterogeneity across studies. We will explore statistical diversity by estimates of treatment effect using forest plots. According to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013113-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG , editor(s), on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>), statistical heterogeneity might not be important when the observed value of I<sup>2</sup> is between 0% and 40%; there might be moderate heterogeneity when I<sup>2</sup> is between 30% and 60%; substantial heterogeneity when I<sup>2</sup> is between 50% and 90%; and considerable heterogeneity when I<sup>2</sup> is greater than 75%. If we identify substantial heterogeneity in future updates of the review, we will report it and explore the possible causes by prespecified subgroup analysis (<a href="#CD013113-sec-0041">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD013113-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to include more than 10 studies, we had planned to create a funnel plot of effect estimates against their standard errors to explore possible small study and publication biases. We had planned to consider possible explanations if we found asymmetry of the funnel plot. </p> <p>However, since we only included one study in this review, we did not assess reporting biases. </p> </section> <section id="CD013113-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We planned to combine the results from similar studies by undertaking a meta‐analysis with a random‐effects model, using <a href="./references#CD013113-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. If substantial or considerable unexplained statistical heterogeneity (I<sup>2</sup> &gt; 50%) had been present, we had planned to omit meta‐analysis and instead report our findings narratively (<a href="#CD013113-sec-0038">Assessment of heterogeneity</a>). Since we only included one study, meta‐analysis was not possible. We will pursue the stated plan in future updates of this review. </p> </section> <section id="CD013113-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ul id="CD013113-list-0012"> <li> <p>Baseline severity of COPD using GOLD spirometric assessment (<a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>) </p> <ul id="CD013113-list-0013"> <li> <p>GOLD 1: mild (FEV<sub>1</sub> ≥ 80% predicted); </p> </li> <li> <p>GOLD 2: moderate (50% ≤ FEV<sub>1</sub> &lt; 80% predicted); </p> </li> <li> <p>GOLD 3: severe (30% ≤ FEV<sub>1</sub> &lt; 50% predicted); </p> </li> <li> <p>GOLD 4: very severe (FEV<sub>1</sub> &lt; 30% predicted). </p> </li> </ul> </li> <li> <p>Type of PPI (lansoprazole or omeprazole or other PPIs). Lansoprazole and omeprazole have been reported to inhibit cytokine production of proinflammatory cytokines and are expected to reduce the frequency of catching common colds (<a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a>). </p> </li> <li> <p>Baseline GERD symptoms: dichotomised as either 'yes' or 'no', according to inclusion criteria. </p> </li> <li> <p>Trial funding sources (financial sponsorship from the pharmaceutical industries or from non‐industry sponsors). </p> </li> </ul> </p> <p>We planned to use the formal test for subgroup interactions in <a href="./references#CD013113-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. </p> <p>We also planned to use the following outcomes in subgroup analyses.</p> <p> <ul id="CD013113-list-0014"> <li> <p>Exacerbations</p> </li> <li> <p>Pneumonia and other serious adverse events</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Acute respiratory infections</p> </li> </ul> </p> <p>We did not undertake these subgroup analyses for the current review because we had insufficient data, but we will include them in future updates. </p> </section> <section id="CD013113-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake sensitivity analyses for the primary outcomes, to assess the robustness of our conclusions. We planned to remove studies at high risk of bias in at least two of the following domains: allocation concealment, blinding of outcome assessors, or incomplete outcome data, based on the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013113-bbs2-0042" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> <p>We also planned to compare the results from a meta‐analysis based on a fixed‐effect model versus those from a random‐effects model. </p> <p>However, given that we included only one study, we did not pursue the planned sensitivity analyses. If we identify sufficient data for future updates of this review, we will undertake the planned sensitivity analyses. </p> </section> <section id="CD013113-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a 'Summary of findings' table using the following outcomes.</p> <p> <ul id="CD013113-list-0015"> <li> <p>Primary outcomes: exacerbations, pneumonia and other serious adverse events.</p> </li> <li> <p>Secondary outcomes: quality of life, lung function indices, acute respiratory infections, disease‐specific adverse events. </p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it related to the study that contributed data for the prespecified outcomes. We used the methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013113-bbs2-0042" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>; <a href="./references#CD013113-bbs2-0084" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al, on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>), using the GRADE working group's software (<a href="./references#CD013113-bbs2-0037" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 27 February 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade the quality of the evidence in the footnotes and also provided further remarks to aid reader's understanding of the our assessment where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013113-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013113-sec-0044"></div> <section id="CD013113-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD013113-sec-0046"> <h4 class="title">Results of the search</h4> <p>We identified 99 records through comprehensive literature searching. Of these, we excluded 86 clearly irrelevant records after screening titles and abstracts. We examined the full‐text articles of 13 records and excluded a further nine records; the remaining four records reported findings from a single study, which we included in the review. Our study selection process is illustrated in <a href="#CD013113-fig-0001">Figure 1</a> in the format of a PRISMA flow diagram. </p> <div class="figure" id="CD013113-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="A PRISMA flow diagram illustrating our study selection process" data-id="CD013113-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>A PRISMA flow diagram illustrating our study selection process</p> </div> </div> </div> </section> <section id="CD013113-sec-0047"> <h4 class="title">Included studies</h4> <p>We identified one study that was eligible for inclusion (<a href="./references#CD013113-sec-0085" title="">Characteristics of included studies</a>). The study was reported as one full‐text peer‐reviewed journal article and three conference abstracts. The study was a single‐blind, multicentre RCT of 103 people with COPD, conducted over a 12‐month period in secondary and tertiary care hospitals in Japan (<a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a>). The study compared the effects of lansoprazole (15 mg/day) plus usual care versus usual care alone on the prevention of exacerbations. <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> excluded people with GERD. Unfortunately, since a long period of time has passed since the end of the study, we were unable to obtain any raw data. </p> </section> <section id="CD013113-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies (<a href="./references#CD013113-bbs2-0002" title="BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . Effect of high-dose omeprazole on airway hyperresponsiveness and pulmonary function in patients with obstructive lung disease. Netherlands Journal of Medicine1995;47:A3 (A1-A42). BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. European Respiratory Journal1998;11(5):1070-4. [PMID: 9648957]">Boeree 1998</a>; <a href="./references#CD013113-bbs2-0003" title="KiljanderTO , SalomaaER , HietanenEK , TerhoEO . Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. European Respiratory Journal2000;16(4):633-8. [PMID: 11106204]">Kiljander 2000</a>; <a href="./references#CD013113-bbs2-0004" title="LiuH . Assessment of anti-reflux treatment on pulmonary ventilation function and inflammatory cytokines in patients with stable chronic obstructive pulmonary disease combined with gastroesophageal reflux. Experimental and Therapeutic Medicine2018;15(6):5528-36. [PMID: 29844808]">Liu 2018</a>; <a href="./references#CD013113-bbs2-0005" title="MillerBE , MistryS , SmartK , ConnollyP , CarpenterDC , CoorayH , et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) - a selective CXCR2 antagonist - in healthy adult subjects. BMC Pharmacology and Toxicology2015;16:18. [PMID: 26092545]">Miller 2015</a>; <a href="./references#CD013113-bbs2-0006" title="NCT00214552. Evaluate the effects on asthma control of rabeprazole given twice daily in subjects with asthma [A double-blind placebo controlled clinical trial to evaluate the effects on asthma control of rabeprazole given twice daily in subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00214552 (first received  22 September 2005). ">NCT00214552</a>; <a href="./references#CD013113-bbs2-0007" title="NCT00523367. COPD patients diagnosed with GERD, COPD exacerbations after treatment with high dose PPI (GERD/COPD) [COPD patients diagnosed with gastroesophageal reflux disease have decreased rates of COPD exacerbations after treatment with high dose proton pump inhibitor therapy (Esomeprazole or Lansoprazole)]. clinicaltrials.gov/ct2/show/NCT00523367 (first received 31 August 2007). ">NCT00523367</a>; <a href="./references#CD013113-bbs2-0008" title="SunZF , ZhangMX , QuGH , LanFJ , LiM , SunSH . Clinical efficacy of antireflux therapy combined with tiotropium bromide in COPD patients with GERD. World Chinese Journal of Digestology2016;9:1412-6. ">Sun 2016</a>; <a href="./references#CD013113-bbs2-0009" title="UMIN000002056. Effects of rabeprazole on acute exacerbation in chronic obstructive pulmonary disease (COPD) patients with acid reflux symptoms. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002502 (first received 8 June 2009). ">UMIN000002056</a>). These are listed in the '<a href="./references#CD013113-sec-0086" title="">Characteristics of excluded studies</a>' table, with reasons for exclusion. For three studies, the reason for exclusion was the type of participants (a study of people with asthma only (<a href="./references#CD013113-bbs2-0006" title="NCT00214552. Evaluate the effects on asthma control of rabeprazole given twice daily in subjects with asthma [A double-blind placebo controlled clinical trial to evaluate the effects on asthma control of rabeprazole given twice daily in subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00214552 (first received  22 September 2005). ">NCT00214552</a>); a study enrolling healthy participants only (<a href="./references#CD013113-bbs2-0005" title="MillerBE , MistryS , SmartK , ConnollyP , CarpenterDC , CoorayH , et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) - a selective CXCR2 antagonist - in healthy adult subjects. BMC Pharmacology and Toxicology2015;16:18. [PMID: 26092545]">Miller 2015</a>); a study of people with chronic cough (<a href="./references#CD013113-bbs2-0003" title="KiljanderTO , SalomaaER , HietanenEK , TerhoEO . Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. European Respiratory Journal2000;16(4):633-8. [PMID: 11106204]">Kiljander 2000</a>)). Participants in two studies received not only PPIs but also an oral prokinetic (mosapride) as part of the acid‐suppressive treatment, so we excluded them (<a href="./references#CD013113-bbs2-0004" title="LiuH . Assessment of anti-reflux treatment on pulmonary ventilation function and inflammatory cytokines in patients with stable chronic obstructive pulmonary disease combined with gastroesophageal reflux. Experimental and Therapeutic Medicine2018;15(6):5528-36. [PMID: 29844808]">Liu 2018</a>; <a href="./references#CD013113-bbs2-0008" title="SunZF , ZhangMX , QuGH , LanFJ , LiM , SunSH . Clinical efficacy of antireflux therapy combined with tiotropium bromide in COPD patients with GERD. World Chinese Journal of Digestology2016;9:1412-6. ">Sun 2016</a>). One study was not an RCT, and had a single‐group assignment design (<a href="./references#CD013113-bbs2-0007" title="NCT00523367. COPD patients diagnosed with GERD, COPD exacerbations after treatment with high dose PPI (GERD/COPD) [COPD patients diagnosed with gastroesophageal reflux disease have decreased rates of COPD exacerbations after treatment with high dose proton pump inhibitor therapy (Esomeprazole or Lansoprazole)]. clinicaltrials.gov/ct2/show/NCT00523367 (first received 31 August 2007). ">NCT00523367</a>). One study was previously registered in a trial registry but, through personal communication with the research director of the responsible institute, we found out that the study had not been executed, so we excluded it (<a href="./references#CD013113-bbs2-0009" title="UMIN000002056. Effects of rabeprazole on acute exacerbation in chronic obstructive pulmonary disease (COPD) patients with acid reflux symptoms. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002502 (first received 8 June 2009). ">UMIN000002056</a>). </p> <p>We also excluded <a href="./references#CD013113-bbs2-0002" title="BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . Effect of high-dose omeprazole on airway hyperresponsiveness and pulmonary function in patients with obstructive lung disease. Netherlands Journal of Medicine1995;47:A3 (A1-A42). BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. European Respiratory Journal1998;11(5):1070-4. [PMID: 9648957]">Boeree 1998</a>. The study was double‐blind and conducted in a tertiary care hospital in the Netherlands, enrolling a total of 36 people with asthma or COPD with airway hyperresponsiveness. The study compared the effects of omeprazole at a daily dose of 80 mg with placebo on pulmonary symptoms and functions over three months (<a href="./references#CD013113-bbs2-0002" title="BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . Effect of high-dose omeprazole on airway hyperresponsiveness and pulmonary function in patients with obstructive lung disease. Netherlands Journal of Medicine1995;47:A3 (A1-A42). BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. European Respiratory Journal1998;11(5):1070-4. [PMID: 9648957]">Boeree 1998</a>). For this study, there was no clear definition of asthma and COPD. We contacted the study authors for further clarification on the definitions of asthma and COPD, and were informed that they applied a so‐called “Dutch hypothesis” definition of asthma and COPD. The Dutch hypothesis is based on the theory asthma and COPD have common origins and clinical expressions, and is suggested to be determined both by endogenous factors such as heredity, sex and age, and exogenous factors such as smoking, air pollution, viruses and allergens (<a href="./references#CD013113-bbs2-0019" title="BleeckerER . Similarities and differences in asthma and COPD. The Dutch hypothesis. Chest2004;126(2 Suppl):93S-5S.">Bleecker 2004</a>; <a href="./references#CD013113-bbs2-0077" title="PostmaDS , WeissST , vanden BergeM , KerstjensHA , KoppelmanGH . Revisiting the Dutch hypothesis. The Journal of Allergy and Clinical Immunology2015;136(3):521-9. [PMID: 26343936]">Postma 2015b</a>). It has been adopted by many researchers to identify heterogeneity in asthma and COPD, and to better define these diseases by phenotype to optimise their treatment (<a href="./references#CD013113-bbs2-0077" title="PostmaDS , WeissST , vanden BergeM , KerstjensHA , KoppelmanGH . Revisiting the Dutch hypothesis. The Journal of Allergy and Clinical Immunology2015;136(3):521-9. [PMID: 26343936]">Postma 2015b</a>). </p> <p>Participants in <a href="./references#CD013113-bbs2-0002" title="BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . Effect of high-dose omeprazole on airway hyperresponsiveness and pulmonary function in patients with obstructive lung disease. Netherlands Journal of Medicine1995;47:A3 (A1-A42). BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. European Respiratory Journal1998;11(5):1070-4. [PMID: 9648957]">Boeree 1998</a> met the recent COPD diagnostic criteria of (FEV<sub>1</sub> &lt; 70%) by <a href="./references#CD013113-bbs2-0036" title="Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed prior to 1 May 2020).">GOLD 2020</a>. However, the included group had extremely high FEV<sub>1</sub> as percentage predicted compared to group of people who would fit in COPD definition, even in the irreversible group. Moreover, the study included only people who were treated with a high dose of inhaled corticosteroid and a positive metacholine test. Although this study might also have included people with COPD, the majority of participants met the definition for asthma. For this reason, we determined that there were not enough numbers to reach a conclusion about the impact of PPI on COPD, and we decided to exclude <a href="./references#CD013113-bbs2-0002" title="BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . Effect of high-dose omeprazole on airway hyperresponsiveness and pulmonary function in patients with obstructive lung disease. Netherlands Journal of Medicine1995;47:A3 (A1-A42). BoereeMJ , PetersFT , PostmaDS , KleibeukerJH . No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. European Respiratory Journal1998;11(5):1070-4. [PMID: 9648957]">Boeree 1998</a> from this review. </p> </section> </section> <section id="CD013113-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The '<a href="./references#CD013113-sec-0085" title="">Characteristics of included studies</a>' table presents further details of 'Risk of bias' assessments and supporting evidence. <a href="#CD013113-fig-0002">Figure 2</a> provides a summary of 'Risk of bias' assessments by domain. We considered included study's risk of bias was largely low or unclear for the majority of domains, although there was a high risk of performance bias because there was no blinding. </p> <div class="figure" id="CD013113-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for the included study." data-id="CD013113-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for the included study. </p> </div> </div> </div> <section id="CD013113-sec-0050"> <h4 class="title">Allocation</h4> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> provided details of the method of random sequence generation, so we judged the study to be at low risk of bias for this domain. However, there was insufficient information on how allocation concealment was performed, so we assigned 'unclear risk of bias' for this domain. </p> </section> <section id="CD013113-sec-0051"> <h4 class="title">Blinding</h4> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> was described as an observer‐blind RCT; participants and study personnel were unblinded and we judged the domain of performance bias to be at 'high risk'. Furthermore, there was no description of the role of the observers, so we assessed the risk of detection bias to be unclear. </p> </section> <section id="CD013113-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>The study reports documented the rates of participant withdrawal. The withdrawal rates were low and balanced between groups. Thus, we judged <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> to be at 'low risk' for attrition bias. </p> </section> <section id="CD013113-sec-0053"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> was not preregistered on appropriate clinical trials registries, and we did not identify a study protocol. Thus, we assessed the study to be at 'unclear risk' of reporting bias. </p> </section> <section id="CD013113-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>We considered whether <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> had other potential sources of bias. Data analysis as reported in the study indicated that, of the 103 randomised participants, three were lost to follow‐up and were excluded from the analysis. This suggests that the study did not use an intention‐to‐treat (ITT) analytical approach. In addition, there appeared to be a baseline imbalance in COPD severity, where the people in the usual care (control) group had a more advanced stage of COPD, based on baseline lung function; however, there were no statistical comparisons available. We are aware that this baseline imbalance would tend to skew the results in favour of PPI use, resulting in a potential overestimation of the treatment effects. However, the randomisation method was appropriate and it was unlikely to have a significant effect on the results. Consequently, we judged <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> to be at 'low risk' for other bias. </p> </section> </section> <section id="CD013113-sec-0055"> <h3 class="title" id="CD013113-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD013113-tbl-0001"><b>Summary of findings 1</b> PPI plus usual care versus usual care alone or chronic obstructive pulmonary disease</a> </p> <p><a href="./full#CD013113-tbl-0001">summary of findings Table 1</a> presents an overview of the results and a summary of our certainty of the evidence. Only one study met the inclusion criteria for this review, so we are reporting the results narratively. </p> <section id="CD013113-sec-0056"> <h4 class="title">PPI plus usual care versus usual care alone</h4> <p>In people with COPD but no history or symptoms of GERD, <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> reported that 12 out of 50 people in the PPI plus usual care group experienced one or more exacerbations, compared to 26 out of 50 in the usual care alone group (RR 0.46, 95% CI 0.26 to 0.81; 100 participants; low‐certainty evidence; <a href="./references#CD013113-fig-0003" title="">Analysis 1.1</a>). The frequency of COPD exacerbations per person in a year was also lower in the PPI plus usual care group than in the usual care alone group（0.34 ± 0.72 vs 1.18 ± 1.40; P &lt; 0.001). However, using GRADE criteria, we judged the evidence for this outcome to be low certainty, as it was from a single small study and there was no blinding. </p> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> also provided information on acute respiratory infections, as the number of people with COPD who experienced one or more episodes of common colds. At the end of 12 month's treatment, the number of participants who experienced one or more common colds (upper respiratory tract infections) per person was slightly lower in the PPI plus usual care group (26 out of 50) than in the usual care alone group (27 out of 50), but the confidence interval was wide (RR 0.96, 95% CI 0.67 to 1.39; 100 participants; very low‐certainty evidence; <a href="./references#CD013113-fig-0004" title="">Analysis 1.2</a>; <a href="./full#CD013113-tbl-0001">summary of findings Table 1</a>). Using GRADE criteria, we judged the evidence for this outcome to be very low certainty. </p> <p>We did not identify any evidence on pneumonia and other serious adverse events, quality of life, lung function test indices or disease‐specific adverse events. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013113-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013113-sec-0057"></div> <section id="CD013113-sec-0058"> <h3 class="title" id="CD013113-sec-0058">Summary of main results</h3> <p>We included only one study, which randomised a total of 103 participants, and we assessed the evidence to be of low to very low certainty. There is currently insufficient evidence to support the use of PPIs in people with COPD, in particular on outcomes such as pneumonia or serious adverse events. </p> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> investigated the effects of lansoprazole plus usual care versus usual care alone in people with COPD but no history or symptoms of GERD. The study measured frequencies of the common cold and COPD exacerbation for 12 months. Findings indicated that lansoprazole plus usual care led to a reduced COPD exacerbation rate compared to usual care alone. <a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> reported data on the common cold (upper respiratory tract infections), but found no difference between groups. The study did not report any data for our other prespecified primary and secondary outcomes, such as pneumonia or serious adverse events, quality of life, lung function indices and disease‐specific adverse events. </p> </section> <section id="CD013113-sec-0059"> <h3 class="title" id="CD013113-sec-0059">Overall completeness and applicability of evidence</h3> <p>We could not conduct a meta‐analysis because this review contained only one study. Instead, we narratively reported the findings. Caution should be used when extrapolating these results to similar populations or other settings, as there was a lack of data and the study did not use a placebo. We could not identify any studies that used PPIs other than lansoprazole, or studies that used low‐dose PPIs as a comparison. </p> <p>There is a lack of evidence to indicate whether treatment with PPIs might play a role in managing COPD, in terms of exacerbations and adverse events. There is also insufficient evidence to clarify the effects of PPIs on quality of life, respiratory function or disease‐specific adverse events. Thus, the evidence for the benefits and harms of PPI interventions for people with COPD is incomplete. Evidence for the treatment's applicability to clinical practice is limited. </p> </section> <section id="CD013113-sec-0060"> <h3 class="title" id="CD013113-sec-0060">Quality of the evidence</h3> <p>Only one study contributed data to this review. Our assessment of its risk of bias indicated a high risk of performance bias due to unblinded participants and personnel. We were unable to pursue clinically meaningful subgroup analysis because we only included one study. We recognised the limitations and methodological shortcomings of the study, and evaluated the certainty of evidence to be low to very low, using the GRADE approach. </p> </section> <section id="CD013113-sec-0061"> <h3 class="title" id="CD013113-sec-0061">Potential biases in the review process</h3> <p>We received support from Cochrane Airways' information specialist to pursue a comprehensive and systematic literature search. Two reviewers independently selected eligible studies and evaluated the included studies following standard Cochrane methodology to minimise bias. We also made every effort to obtain missing study characteristics/data where appropriate by contacting the original study authors. As with any systematic review, we are aware of the potential publication bias in this Cochrane Review. Since we only included one study, we did not explore publication bias. For future updates, if the number of included studies exceeds 10, we will follow recommended methods to test for publication bias. </p> </section> <section id="CD013113-sec-0062"> <h3 class="title" id="CD013113-sec-0062">Agreements and disagreements with other studies or reviews</h3> <p>We were unable to identify another systematic review investigating the efficacy and safety of PPIs in people with COPD. To our knowledge, this is the first attempt at systematically identifying, appraising and synthesising evidence on the benefits and harms of PPIs for COPD. The inclusion of one small‐scale study of low to very low quality indicates that, at the moment, no concrete conclusions can be drawn regarding the effectiveness PPI as a treatment option for COPD. </p> <p><a href="./references#CD013113-bbs2-0001" title="SasakiT , KatsutoshiN , HiroyasuY , ToshihiroN , MutsuoY . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. SasakiT , NakayamaK , YasudaH , YoshidaM , AsamuraT , OhruiT , et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. Journal of the American Geriatrics Society2009;57(8):1453-7. [PMID: 19515110]SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . A proton pump inhibitor lansoprazole reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. SasakiT , NakayamaK , YasudaH , YoshidaM , InoueD , YamayaM . The proton pump inhibitor, lansoprazole, reduces frequency of exacerbations in patients with chronic obstructive pulmonary disease. In: Chest 2011 Annual Meeting; 2011 Oct 22-26; Honolulu. 2011. ">Sasaki 2009</a> suggested that larger studies should be conducted to determine the efficacy and safety of PPI in people with COPD. Due to the limited data available from the review, it is not possible to assess whether PPIs have a positive or negative effect on COPD exacerbation and quality of life of people with COPD. However, planned future studies may help to resolve the uncertainty of PPI interventions for people with COPD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013113-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/urn:x-wiley:14651858:media:CD013113:CD013113-FIG-01" target="_blank"><b></b></a></p> </div><img alt="A PRISMA flow diagram illustrating our study selection process" data-id="CD013113-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_t/tCD013113-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>A PRISMA flow diagram illustrating our study selection process</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013113-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/urn:x-wiley:14651858:media:CD013113:CD013113-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for the included study." data-id="CD013113-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_t/tCD013113-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for the included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013113-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/urn:x-wiley:14651858:media:CD013113:CD013113-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PPI plus usual care vs usual care alone, Outcome 1: People with one or more exacerbations" data-id="CD013113-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_t/tCD013113-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PPI plus usual care vs usual care alone, Outcome 1: People with one or more exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references#CD013113-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013113-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/urn:x-wiley:14651858:media:CD013113:CD013113-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PPI plus usual care vs usual care alone, Outcome 2: Acute respiratory infections" data-id="CD013113-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_t/tCD013113-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PPI plus usual care vs usual care alone, Outcome 2: Acute respiratory infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references#CD013113-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/media/CDSR/CD013113/image_n/nCD013113-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013113-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PPI plus usual care versus usual care alone or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Usual care plus PPI compared to Usual care plus alone for chronic obstructive pulmonary disease</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic obstructive pulmonary disease<br/><b>Setting:</b> hospital outpatients in Japan (three secondary care hospitals and one tertiary care hospital)<br/><b>Intervention:</b> Usual care plus PPI<br/><b>Comparison:</b> Usual care plus alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Usual care plus alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Usual care plus PPI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Exacerbation rate (participants with one or more)</p> <p>study duration: 12 months</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.46<br/>(0.26 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The frequency of exacerbations improved with intervention.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>520 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1,000<br/>(135 to 421) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia and other serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function indices</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute respiratory infections</p> <p>study duration: 12 months</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.67 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear benefit or harm from PPI</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1,000<br/>(362 to 751) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐specific adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>PPI</b> : proton pump inhibitor; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for imprecision: single small trial describes this result </p> <p><sup>b</sup>Downgraded by one level for study limitations: no blinding of participants and personnel </p> <p><sup>c</sup>Downgraded by one level for study limitations: the rate and number of common colds using outcomes that tend to be subjective </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PPI plus usual care versus usual care alone or chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/full#CD013113-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013113-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PPI plus usual care vs usual care alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 People with one or more exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Acute respiratory infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PPI plus usual care vs usual care alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013113.pub2/references#CD013113-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013113.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013113-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013113-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013113-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013113-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013113-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013113-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013113-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013113-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013113-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013113\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013113\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013113\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013113\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013113\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013113.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013113.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013113.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013113.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013113.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727349919"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013113.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727349923"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013113.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea9e7cf6f9377',t:'MTc0MDcyNzM1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 